Midostaurin - CAS 120685-11-2
Catalog number: B0084-162132
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Midostaurin is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-162132 20 mg $298 In stock
Bulk Inquiry
Light yellow to yellow Solid
PKC 412; PKC412A; CGP 41251; Benzoylstaurosporine; 4'-N-Benzoylstaurosporine; Cgp 41251; Cgp 41 251
Canonical SMILES:
Current Developer:
Novartis International AG.
1.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P;Vachhani P;Cortes JE Curr Treat Options Oncol. 2017 Mar;18(3):17. doi: 10.1007/s11864-017-0456-2.
Approximately 40-45% of younger and 10-20% of older adults with acute myeloid leukemia (AML) will be cured with current standard chemotherapy. The outlook is particularly gloomy for patients with relapsed and/or refractory disease (cure rates no higher than 10%). Allogeneic hematopoietic stem cell transplantation (HSCT), the only realistic hope of cure for these patients, is an option for only a minority. In recent years, much has been learned about the genomic and epigenomic landscapes of AML, and the clonal architecture of both de novo and secondary AML has begun to be unraveled. These advances have paved the way for rational drug development as new "drugable" targets have emerged. Although no new drug has been approved for AML in over four decades, with the exception of gemtuzumab ozogamycin, which was subsequently withdrawn, there is progress on the horizon with the possible regulatory approval soon of agents such as CPX-351 and midostaurin, the Food and Drug Administration "breakthrough" designation granted to venetoclax, and promising agents such as the IDH inhibitors AG-221 and AG-120, the smoothened inhibitor glasdegib and the histone deacetylase inhibitor pracinostat. In our practice, we treat most patients with relapsed/refractory AML on clinical trials, taking into consideration their prior treatment history and response to the same.
2.Interference with the contractile machinery of the fibroblastic chondrocyte cytoskeleton induces re-expression of the cartilage phenotype through involvement of PI3K, PKC and MAPKs.
Rottmar M;Mhanna R;Guimond-Lischer S;Vogel V;Zenobi-Wong M;Maniura-Weber K Exp Cell Res. 2014 Jan 15;320(2):175-87. doi: 10.1016/j.yexcr.2013.11.004. Epub 2013 Nov 15.
Chondrocytes rapidly lose their phenotypic expression of collagen II and aggrecan when grown on 2D substrates. It has generally been observed that a fibroblastic morphology with strong actin-myosin contractility inhibits chondrogenesis, whereas chondrogenesis may be promoted by depolymerization of the stress fibers and/or disruption of the physical link between the actin stress fibers and the ECM, as is the case in 3D hydrogels. Here we studied the relationship between the actin-myosin cytoskeleton and expression of chondrogenic markers by culturing fibroblastic chondrocytes in the presence of cytochalasin D and staurosporine. Both drugs induced collagen II re-expression; however, renewed glycosaminoglycan synthesis could only be observed upon treatment with staurosporine. The chondrogenic effect of staurosporine was augmented when blebbistatin, an inhibitor of myosin/actin contractility, was added to the staurosporine-stimulated cultures. Furthermore, in 3D alginate cultures, the amount of staurosporine required to induce chondrogenesis was much lower compared to 2D cultures (0.625 nM vs. 2.5 nM). Using a selection of specific signaling pathway inhibitors, it was found that PI3K-, PKC- and p38-MAPK pathways positively regulated chondrogenesis while the ERK-pathway was found to be a negative regulator in staurosporine-induced re-differentiation, whereas down-regulation of ILK by siRNA indicated that ILK is not determining for chondrocyte re-differentiation.
3.C6 ceramide motivates the anticancer sensibility induced by PKC412 in preclinical head and neck squamous cell carcinoma models.
Zhu Y;Wang C;Zhou Y;Ma N;Zhou J J Cell Physiol. 2018 Jul 3. doi: 10.1002/jcp.26831. [Epub ahead of print]
The purpose of this study was to evaluate the anti-head and neck squamous cell carcinoma (anti-HNSCC) cell activity by C6 ceramide and multikinase inhibitor PKC412. Experiments were performed on HNSCC cell lines (SQ20B and SCC-9) and primary human oral carcinoma cells. Results showed that PKC412 inhibited HNSCC cell proliferation without provoking apoptosis activation. Cotreatment of C6 ceramide significantly augmented PKC412-induced lethality in HNSCC cells. PKC412 decreased Akt-mammalian target of rapamycin (mTOR) activation in HNSCC cells, facilitated with cotreatment of C6 ceramide. In contrast, exogenous expression of a constitutively active Akt restored Akt-mTOR activation and attenuated lethality by the cotreatment. We propose that Mcl-1 is a primary resistance factor of PKC412. The cytotoxicity of PKC412 in HNSCC cells was potentiated with Mcl-1 short hairpin RNA knockdown, but was attenuated with Mcl-1 overexpression. Intriguingly, C6 ceramide downregulated Mcl-1 in HNSCC cells. In vivo, PKC412 oral administration inhibited SQ20B xenograft tumor growth in severe combined immunodeficient mice. The antitumor activity of PKC412 was further sensitized with coadministration of liposomal C6 ceramide.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PKC Products

CAS 113731-96-7 PKC (19-36)

PKC (19-36)
(CAS: 113731-96-7)

PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C (IC50 = 0.18 μM).

CAS 1438881-19-6 CRT0066854

(CAS: 1438881-19-6)

CRT0066854 is a selective and ATP-competitive inhibitor of the atypical PKC isoenzymes (IC50 values 639 nM and 132 nM for full-length PKCζ, PKCι, respectively)....

CAS 90365-57-4 (-)-Indolactam V

(-)-Indolactam V
(CAS: 90365-57-4)

(-)-Indolactam V is an indole alkaloid compound which activates protein kinase C (PKC), which strongly directs human ES cell-derived definitive endoderm into pa...

CAS 151342-35-7 Ro 32-0432 hydrochloride

Ro 32-0432 hydrochloride
(CAS: 151342-35-7)

Ro 32-0432 hydrochloride is a selective and orally active inhibitor of PKC displaying a 10-fold greater selectivity for PKC-&alpha (IC50 = 9.3 nM); and a 4-fold...

CAS 17673-25-5 Phorbol

(CAS: 17673-25-5)

Phorbol, derived from the roots of Euphorbia pekinensis Rupr., as a tumor promoter it is able to activate protein kinase C.

NSC305787 hydrochloride
(CAS: 53868-26-1)

NSC305787 hydrochloride is a small molecule inhibitor of PKC (IC50=8.3 μM) that directly inhibits ezrin protein as an approach to prevent tumor metastasis.

CAS 82-08-6 Rottlerin

(CAS: 82-08-6)

Rottlerin, a principal phenolic compound of the Kamala plant Mallotus philippinensis, originally reported to inhibit PKC isoforms, especially PKCδ and CAM-KIII....

CAS 169939-94-0 Ruboxistaurin

(CAS: 169939-94-0)

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...

CAS 120685-11-2 Midostaurin

(CAS: 120685-11-2)

Midostaurin is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

CAS 172308-76-8 PKC β pseudosubstrate

PKC β pseudosubstrate
(CAS: 172308-76-8)

PKC β pseudosubstrate, a selective cell-permeable peptide inhibitor of protein kinase C (IC50 ~ 0.5 μM), consists of amino acids 19-31 of PKC pseudosubstrate do...

CAS 170364-57-5 Enzastaurin

(CAS: 170364-57-5)

Enzastaurin is a protein kinase C beta inhibitor with 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Binding to the ATP-binding site, enzastaurin select...

CAS 164658-13-3 CGP60474

(CAS: 164658-13-3)

CGP60474 is a promising inhibitor of PKC with a high degree of selectivity versus other serine/threonine and tyrosine kinases and show competitive kinetics rela...

CAS 108930-17-2 H-7 dihydrochloride

H-7 dihydrochloride
(CAS: 108930-17-2)

H-7 dihydrochloride is a protein kinase inhibitor (IC50 = 6.0, 5.8, 3.0 and 97.0 μM for inhibition of PKC, PKG, PKA and myosin light chain kinase, respectively)...

CRT 0066854 hydrochloride

The hydrochloride salt form of CRT 0066854, which has been found to be a PKC inhibitor.

CAS 1874276-76-2 LXS196

(CAS: 1874276-76-2)

LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under clinical trials for the treatment of uveal melanoma, the most common cancer of the e...

CAS 37558-16-0 Phorbol 12,13-dibutyrate

Phorbol 12,13-dibutyrate
(CAS: 37558-16-0)

Phorbol 12,13-dibutyrate, a protein kinase C activator, stimulates the phosphorylation of Na+,K+- ATPase, thereby inhibiting its activity.

CAS 28399-31-7 FR 236924

FR 236924
(CAS: 28399-31-7)

FR 236924 is a selective PKCε activator with > 7-fold selectivity over other PKC isozymes. FR 236924 promotes glutamate release via presynaptic α7 nicotinic rec...

CAS 30220-46-3 Ingenol

(CAS: 30220-46-3)

Ingenol, the analogue of Ingenol 3-Angelate found in the seeds of Euphorbia lathyris L, is an extremely weak PKC (protein kinase C) activator ( Ki=30 μM, ED50=2...

CAS 83314-01-6 Bryostatin 1

Bryostatin 1
(CAS: 83314-01-6)

Bryostatin 1, a structurally unique macrolactone marine natural product, is a protein kinase C (PKC) activator that binds with high affinity (Ki = 1.35 nM). Bry...

(CAS: 785718-37-8)

NSC305787 is a small molecule inhibitor of PKC. Its IC50 value is 8.3 μM, 9.4 μM, 55 μM for PKCΙ phosphorylation of recombinant ezrin, moesin and radixin. It is...

Chemical Structure

CAS 120685-11-2 Midostaurin

Quick Inquiry

Verification code

Featured Items